Literature DB >> 19443719

Is routine pupil dilation safe among asian patients with diabetes?

Gavin S Tan1, Ching-Yee Wong, Tien Yin Wong, Chitra V Govindasamy, Edmund Y Wong, Ian Y Yeo, Tin Aung.   

Abstract

PURPOSE: To investigate the risk of acute angle closure (AAC), changes in intraocular pressure (IOP), and factors associated with these outcomes after routine pupil dilation in a cohort of Asian subjects with diabetes mellitus.
METHODS: The study was a prospective observational case series of 1910 consecutive Asian subjects newly referred for assessment of diabetic retinopathy at a tertiary clinic. All subjects underwent routine pupil dilation unless there was a prior history of angle-closure glaucoma. Noncontact air-puff tonometry was used to assess IOP, which was measured by the same observer before and 1 hour after pupil dilation. Subjects were assessed for signs and symptoms of AAC before leaving the clinic, and their charts were also subsequently reviewed for revisits with AAC.
RESULTS: Of the 1910 subjects who participated, none developed AAC. Sixty-nine subjects (3.6%, 95% CI: 2.8%-4.5%) showed an increase in IOP of >or=5 mm Hg in the either eye, 37 subjects (1.9%, 95% CI: 1.4%-2.6%) had a postdilation IOP >25 mm Hg in either eye, and only 10 subjects (0.52%, 95% CI: 0.25%-0.96%) had an increase in IOP >or=5 mm Hg and had a postdilation IOP >25 mm Hg in either eye. The level of predilation IOP and a known history of glaucoma were significant risk factors for a postdilation IOP >or=25 mm Hg.
CONCLUSIONS: In this cohort of Asian persons with diabetes, the risk of AAC was insignificant after routine dilation of pupils for fundus examination. These data substantiate the safety of routine dilation of pupils in Asian patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443719     DOI: 10.1167/iovs.08-2745

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  The change in intraocular pressure after pupillary dilation in eyes with pseudoexfoliation glaucoma, primary open angle glaucoma, and eyes of normal subjects.

Authors:  Eray Atalay; Nevbahar Tamçelik; Ceyhun Arici; Ahmet Özkök; Metin Dastan
Journal:  Int Ophthalmol       Date:  2014-03-31       Impact factor: 2.031

Review 2.  Advances in Retinal Imaging and Applications in Diabetic Retinopathy Screening: A Review.

Authors:  Beau J Fenner; Raymond L M Wong; Wai-Ching Lam; Gavin S W Tan; Gemmy C M Cheung
Journal:  Ophthalmol Ther       Date:  2018-11-10

3.  Diabetic retinopathy screening guidelines in India: All India Ophthalmological Society diabetic retinopathy task force and Vitreoretinal Society of India Consensus Statement.

Authors:  Rajiv Raman; Kim Ramasamy; Ramachandran Rajalakshmi; Sobha Sivaprasad; S Natarajan
Journal:  Indian J Ophthalmol       Date:  2021-03       Impact factor: 1.848

Review 4.  Various models for diabetic retinopathy screening that can be applied to India.

Authors:  Ramachandran Rajalakshmi; Vijayaraghavan Prathiba; Padmaja Kumari Rani; Viswanathan Mohan
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

5.  Use of offline artificial intelligence in a smartphone-based fundus camera for community screening of diabetic retinopathy.

Authors:  Astha Jain; Radhika Krishnan; Ashwini Rogye; Sundaram Natarajan
Journal:  Indian J Ophthalmol       Date:  2021-11       Impact factor: 1.848

6.  Effect of Mydriasis-Caused Intraocular Pressure Changes on Corneal Biomechanical Metrics.

Authors:  Yufeng Ye; Yi Li; Zehui Zhu; Anas Ziad Masoud Abu Said; Kevin Nguelemo Mayopa; Stephen Akiti; Chengyi Huang; Bernardo T Lopes; Ashkan Eliasy; Yuanyuan Miao; Junjie Wang; Xiaobo Zheng; Shihao Chen; Fangjun Bao; Ahmed Elsheikh
Journal:  Front Bioeng Biotechnol       Date:  2021-11-26

7.  Is there an association of socioeconomic deprivation with acute primary angle closure?

Authors:  Edward Saxby; Kelvin Cheng; Niamh O'Connell; Roshini Sanders; Pankaj Kumar Agarwal
Journal:  Eye (Lond)       Date:  2021-06-11       Impact factor: 4.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.